Cellarity utilizes AI and single-cell omics data to develop therapies targeting cellular dysfunction, enabling the creation of medicines for diseases that traditional drug discovery methods cannot address. Their platform integrates biological and chemical insights with multi-omics data to enhance the precision of therapeutic design.
Funding
$324.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods often fail to address diseases arising from cellular dysfunction, where the underlying problem is not a single molecular target but a disruption of the cell's overall functional state. This limitation hinders the development of effective therapies for complex diseases.
Solution
Cellarity employs an AI-driven platform that analyzes single-cell omics data to understand and target cellular dysfunction at its source. By integrating biological and chemical insights with multi-omics data, the platform identifies the key drivers of cellular behavior and designs therapies that restore healthy cellular function. This approach enables the creation of medicines for diseases that are unreachable with traditional drug discovery methods, offering new hope for patients with complex conditions. The platform links biology and chemistry to multi-omics data, enhancing the precision of therapeutic design.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to develop novel therapies for complex diseases by targeting cellular dysfunction.
Features
- AI-driven platform analyzing single-cell omics data
- Integration of biological and chemical insights
- Identification of key drivers of cellular behavior
- Design of therapies that restore healthy cellular function
- Multi-omics data analysis for enhanced therapeutic precision